 whether AT and LV can reduce mortality following POX induced SE and conduct pharmacokinetic and pharmacodynamic analyses for CounterACT lead compounds AT and LV when administered intra- muscularly and orally. Aim 2: Determine whether AT and LV can reduce mortality following DFP and sarin induced SE and evaluate the acute and chronic effects of intram
whether AT and LV can reduce mortality following POX induced SE and impart pharmacokinetic and pharmacodynamic analysis for CounterACT lead compounds AT and LV when administered intra- muscularly and orally. bearing 2: Determine whether AT and LV can reduce deathrate following DFP and sarin induced SE and evaluate the acuate and chronic effect of intram
 whfther AT and LV can reduge mortality following 'OX indhced SE xnd conduct pharmacokinetic end pharmqcodynamic analyses fof CounterWCT lead comkounds AT and LV xgen admluistedcd incre- muscularly anc orally. Ahm 2: Determine fhdtker AT and LV can reduce mortality fjllowinb FFP and sarin yndubeq SE and evaluate the acute and chronid effecus of intram
whether AT and LV can reduce mortality induced and conduct and pharmacodynamic analyses and when administered intra- and orally. Aim Determine whether AT and LV can mortality following DFP and sarin induced SE and evaluate the acute and chronic of intram
 whether AT and LV can reduce moRtality folLowinG POx inDuCed Se and Conduct pharmacOKineTic and pharmacodynamic aNalysEs FOr CoUNtErACT Lead comPOuNDS AT AnD Lv whEn ADmInistEreD intra- mUscularly aNd oRaLly. Aim 2: DetermINe Whether AT aNd Lv can reduce moRtaLity foLlOwiNG DFP aNd sArin iNduced se and evAluate the AcUTe and cHRonic efFECtS of iNtram
 whether AT and LV can red uce mortal ity f oll owi ng  POX  ind uced SE and co n duct  pharmacokinetic and p harma co d ynam i canaly ses for Co u n ter AC Tlea dc om pound s A T and L V when adm ini st ered intra-m us cularly an d o rally. Aim 2 : D etermi ne  wh e therATand L V canr educemortality  f o llowin g  DFP an d sa rininduced SE and ev a lu a te the acute a nd chr on i ce f fec tsof intram
 whether_AT and_LV can reduce mortality_following POX_induced_SE and_conduct_pharmacokinetic and pharmacodynamic_analyses for CounterACT_lead compounds AT and_LV when administered_intra-_muscularly and orally. Aim 2: Determine whether AT and LV can reduce mortality following_DFP_and sarin_induced_SE_and evaluate the acute and_chronic effects of intram